Review



recombinant human hpse  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems recombinant human hpse
    PMN antifungal activity in VCM spiked with HS or treated with HPSEs. Vaginal swab samples were collected from three groups: women with RVVC experiencing a symptomatic acute episode of VVC (symptomatic group, n = 31), those in asymptomatic remission (asymptomatic group, n = 14), and healthy women without a history of frequent VVC (control group, n = 16). The data sets included an additional five follow-up swabs collected from women in the symptomatic and asymptomatic groups. Detached swab tips were suspended individually in 1 mL RPMI 1640 medium to release vaginal secretions and cellular content. Supernatants were sterile-filtered as VCM. PMNs (5 × 10 5 ) isolated from peripheral blood of healthy volunteers were incubated with C. albicans cells (1 × 10 5 ) in 100 µL of VCM or RPMI medium for 3 h at 37°C with 5% CO 2 . Controls consisted of C. albicans cultured alone in VCM or RPMI medium and were used to calculate % killing. ( A ) VCM samples with normal killing activity (non-inhibitory VCM, gray bar) were spiked with purified porcine HS (500 µg/mL) and reevaluated for PMN killing activity (blue bar). Spiked non-inhibitory VCM was then pretreated with r Ph <t>HPSE</t> (3 ng/mL) and reevaluated for PMN killing activity (red bar). ( B ) VCM samples with low killing activity (inhibitory VCM, solid blue bar) were pretreated with rhHPSE (4 µg/mL, red-dotted bar) or r Ph HPSE (3 ng/mL, red-striped bar) and reevaluated for PMN killing activity. After coculture, viable C. albicans cells were enumerated by quantitative plate counts. Data were analyzed using the one-way ANOVA and Bonferroni’s post-test. Bar heights and error bars represent group means ± SEM for % killing values across independent replicates of unique VCM samples. The graphs represent cumulative data from three to four experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.
    Recombinant Human Hpse, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 29 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+heparanase/Recombinant+Human+Active+Heparanase%2FHPSE+Protein%2C+CF/pmc12974118-120-10-16
    Average 94 stars, based on 29 article reviews
    recombinant human hpse - by Bioz Stars, 2026-11
    94/100 stars

    Images

    1) Product Images from "Elevated vaginal heparan sulfate correlates with impaired neutrophil killing of Candida albicans in women with vulvovaginal candidiasis"

    Article Title: Elevated vaginal heparan sulfate correlates with impaired neutrophil killing of Candida albicans in women with vulvovaginal candidiasis

    Journal: Infection and Immunity

    doi: 10.1128/iai.00709-25

    PMN antifungal activity in VCM spiked with HS or treated with HPSEs. Vaginal swab samples were collected from three groups: women with RVVC experiencing a symptomatic acute episode of VVC (symptomatic group, n = 31), those in asymptomatic remission (asymptomatic group, n = 14), and healthy women without a history of frequent VVC (control group, n = 16). The data sets included an additional five follow-up swabs collected from women in the symptomatic and asymptomatic groups. Detached swab tips were suspended individually in 1 mL RPMI 1640 medium to release vaginal secretions and cellular content. Supernatants were sterile-filtered as VCM. PMNs (5 × 10 5 ) isolated from peripheral blood of healthy volunteers were incubated with C. albicans cells (1 × 10 5 ) in 100 µL of VCM or RPMI medium for 3 h at 37°C with 5% CO 2 . Controls consisted of C. albicans cultured alone in VCM or RPMI medium and were used to calculate % killing. ( A ) VCM samples with normal killing activity (non-inhibitory VCM, gray bar) were spiked with purified porcine HS (500 µg/mL) and reevaluated for PMN killing activity (blue bar). Spiked non-inhibitory VCM was then pretreated with r Ph HPSE (3 ng/mL) and reevaluated for PMN killing activity (red bar). ( B ) VCM samples with low killing activity (inhibitory VCM, solid blue bar) were pretreated with rhHPSE (4 µg/mL, red-dotted bar) or r Ph HPSE (3 ng/mL, red-striped bar) and reevaluated for PMN killing activity. After coculture, viable C. albicans cells were enumerated by quantitative plate counts. Data were analyzed using the one-way ANOVA and Bonferroni’s post-test. Bar heights and error bars represent group means ± SEM for % killing values across independent replicates of unique VCM samples. The graphs represent cumulative data from three to four experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.
    Figure Legend Snippet: PMN antifungal activity in VCM spiked with HS or treated with HPSEs. Vaginal swab samples were collected from three groups: women with RVVC experiencing a symptomatic acute episode of VVC (symptomatic group, n = 31), those in asymptomatic remission (asymptomatic group, n = 14), and healthy women without a history of frequent VVC (control group, n = 16). The data sets included an additional five follow-up swabs collected from women in the symptomatic and asymptomatic groups. Detached swab tips were suspended individually in 1 mL RPMI 1640 medium to release vaginal secretions and cellular content. Supernatants were sterile-filtered as VCM. PMNs (5 × 10 5 ) isolated from peripheral blood of healthy volunteers were incubated with C. albicans cells (1 × 10 5 ) in 100 µL of VCM or RPMI medium for 3 h at 37°C with 5% CO 2 . Controls consisted of C. albicans cultured alone in VCM or RPMI medium and were used to calculate % killing. ( A ) VCM samples with normal killing activity (non-inhibitory VCM, gray bar) were spiked with purified porcine HS (500 µg/mL) and reevaluated for PMN killing activity (blue bar). Spiked non-inhibitory VCM was then pretreated with r Ph HPSE (3 ng/mL) and reevaluated for PMN killing activity (red bar). ( B ) VCM samples with low killing activity (inhibitory VCM, solid blue bar) were pretreated with rhHPSE (4 µg/mL, red-dotted bar) or r Ph HPSE (3 ng/mL, red-striped bar) and reevaluated for PMN killing activity. After coculture, viable C. albicans cells were enumerated by quantitative plate counts. Data were analyzed using the one-way ANOVA and Bonferroni’s post-test. Bar heights and error bars represent group means ± SEM for % killing values across independent replicates of unique VCM samples. The graphs represent cumulative data from three to four experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.

    Techniques Used: Activity Assay, Control, Sterility, Isolation, Incubation, Cell Culture, Purification

    Related Articles

    Control:

    Article Title: Investigation into the binding domains of platelet factor 4 unlocks new avenues for the design and synthesis of selective sulfated pseudo-tetrasaccharide aminoglycoside ligands.
    Article Snippet: .. In 0.6 mL LowBind Eppendorf tubes, 42 μL of test compound solution (paromomycin or neomycin analogs in Milli-Q water) or Milli-Q water (vehicle control) was mixed with 42 μL of recombinant human heparanase (5.3 nM; R&D Systems, Cat. No. 7570-GH) in assay buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 % CHAPS). ..

    Recombinant:

    Article Title: Investigation into the binding domains of platelet factor 4 unlocks new avenues for the design and synthesis of selective sulfated pseudo-tetrasaccharide aminoglycoside ligands.
    Article Snippet: .. In 0.6 mL LowBind Eppendorf tubes, 42 μL of test compound solution (paromomycin or neomycin analogs in Milli-Q water) or Milli-Q water (vehicle control) was mixed with 42 μL of recombinant human heparanase (5.3 nM; R&D Systems, Cat. No. 7570-GH) in assay buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 % CHAPS). ..

    Article Title: Chemoenzymatic synthesis of sulfur-linked sugar polymers as heparanase inhibitors
    Article Snippet: .. A gel-based assay was used to monitor the catalytic action of recombinant human heparanase (R&D Systems; Minneapolis, MN) on polysaccharide substrates. ..

    Article Title: Chemoenzymatic synthesis of sulfur-linked sugar polymers as heparanase inhibitors.
    Article Snippet: .. A gel-based assay was used to monitor the catalytic action of recombinant human heparanase (R&D Systems; Minneapolis, MN) on polysaccharide substrates. ..



    Similar Products

    human heparanase elisa kit  (Cusabio)
    94
    Cusabio human heparanase elisa kit
    Human Heparanase Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+heparanase/Human+Heparanase%2CHPA+ELISA+kit/pm41917995-87-72-79
    Average 94 stars, based on 1 article reviews
    human heparanase elisa kit - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    recombinant human hpse  (R&D Systems)
    94
    R&D Systems recombinant human hpse
    PMN antifungal activity in VCM spiked with HS or treated with HPSEs. Vaginal swab samples were collected from three groups: women with RVVC experiencing a symptomatic acute episode of VVC (symptomatic group, n = 31), those in asymptomatic remission (asymptomatic group, n = 14), and healthy women without a history of frequent VVC (control group, n = 16). The data sets included an additional five follow-up swabs collected from women in the symptomatic and asymptomatic groups. Detached swab tips were suspended individually in 1 mL RPMI 1640 medium to release vaginal secretions and cellular content. Supernatants were sterile-filtered as VCM. PMNs (5 × 10 5 ) isolated from peripheral blood of healthy volunteers were incubated with C. albicans cells (1 × 10 5 ) in 100 µL of VCM or RPMI medium for 3 h at 37°C with 5% CO 2 . Controls consisted of C. albicans cultured alone in VCM or RPMI medium and were used to calculate % killing. ( A ) VCM samples with normal killing activity (non-inhibitory VCM, gray bar) were spiked with purified porcine HS (500 µg/mL) and reevaluated for PMN killing activity (blue bar). Spiked non-inhibitory VCM was then pretreated with r Ph <t>HPSE</t> (3 ng/mL) and reevaluated for PMN killing activity (red bar). ( B ) VCM samples with low killing activity (inhibitory VCM, solid blue bar) were pretreated with rhHPSE (4 µg/mL, red-dotted bar) or r Ph HPSE (3 ng/mL, red-striped bar) and reevaluated for PMN killing activity. After coculture, viable C. albicans cells were enumerated by quantitative plate counts. Data were analyzed using the one-way ANOVA and Bonferroni’s post-test. Bar heights and error bars represent group means ± SEM for % killing values across independent replicates of unique VCM samples. The graphs represent cumulative data from three to four experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.
    Recombinant Human Hpse, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+heparanase/Recombinant+Human+Active+Heparanase%2FHPSE+Protein%2C+CF/pmc12974118-120-10-16
    Average 94 stars, based on 1 article reviews
    recombinant human hpse - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    heparinase  (R&D Systems)
    94
    R&D Systems heparinase
    PMN antifungal activity in VCM spiked with HS or treated with HPSEs. Vaginal swab samples were collected from three groups: women with RVVC experiencing a symptomatic acute episode of VVC (symptomatic group, n = 31), those in asymptomatic remission (asymptomatic group, n = 14), and healthy women without a history of frequent VVC (control group, n = 16). The data sets included an additional five follow-up swabs collected from women in the symptomatic and asymptomatic groups. Detached swab tips were suspended individually in 1 mL RPMI 1640 medium to release vaginal secretions and cellular content. Supernatants were sterile-filtered as VCM. PMNs (5 × 10 5 ) isolated from peripheral blood of healthy volunteers were incubated with C. albicans cells (1 × 10 5 ) in 100 µL of VCM or RPMI medium for 3 h at 37°C with 5% CO 2 . Controls consisted of C. albicans cultured alone in VCM or RPMI medium and were used to calculate % killing. ( A ) VCM samples with normal killing activity (non-inhibitory VCM, gray bar) were spiked with purified porcine HS (500 µg/mL) and reevaluated for PMN killing activity (blue bar). Spiked non-inhibitory VCM was then pretreated with r Ph <t>HPSE</t> (3 ng/mL) and reevaluated for PMN killing activity (red bar). ( B ) VCM samples with low killing activity (inhibitory VCM, solid blue bar) were pretreated with rhHPSE (4 µg/mL, red-dotted bar) or r Ph HPSE (3 ng/mL, red-striped bar) and reevaluated for PMN killing activity. After coculture, viable C. albicans cells were enumerated by quantitative plate counts. Data were analyzed using the one-way ANOVA and Bonferroni’s post-test. Bar heights and error bars represent group means ± SEM for % killing values across independent replicates of unique VCM samples. The graphs represent cumulative data from three to four experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.
    Heparinase, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+heparanase/Recombinant+Human+Active+Heparanase%2FHPSE+Protein%2C+CF/pm41440920-182-11-19
    Average 94 stars, based on 1 article reviews
    heparinase - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    recombinant human active heparanase  (R&D Systems)
    94
    R&D Systems recombinant human active heparanase
    PMN antifungal activity in VCM spiked with HS or treated with HPSEs. Vaginal swab samples were collected from three groups: women with RVVC experiencing a symptomatic acute episode of VVC (symptomatic group, n = 31), those in asymptomatic remission (asymptomatic group, n = 14), and healthy women without a history of frequent VVC (control group, n = 16). The data sets included an additional five follow-up swabs collected from women in the symptomatic and asymptomatic groups. Detached swab tips were suspended individually in 1 mL RPMI 1640 medium to release vaginal secretions and cellular content. Supernatants were sterile-filtered as VCM. PMNs (5 × 10 5 ) isolated from peripheral blood of healthy volunteers were incubated with C. albicans cells (1 × 10 5 ) in 100 µL of VCM or RPMI medium for 3 h at 37°C with 5% CO 2 . Controls consisted of C. albicans cultured alone in VCM or RPMI medium and were used to calculate % killing. ( A ) VCM samples with normal killing activity (non-inhibitory VCM, gray bar) were spiked with purified porcine HS (500 µg/mL) and reevaluated for PMN killing activity (blue bar). Spiked non-inhibitory VCM was then pretreated with r Ph <t>HPSE</t> (3 ng/mL) and reevaluated for PMN killing activity (red bar). ( B ) VCM samples with low killing activity (inhibitory VCM, solid blue bar) were pretreated with rhHPSE (4 µg/mL, red-dotted bar) or r Ph HPSE (3 ng/mL, red-striped bar) and reevaluated for PMN killing activity. After coculture, viable C. albicans cells were enumerated by quantitative plate counts. Data were analyzed using the one-way ANOVA and Bonferroni’s post-test. Bar heights and error bars represent group means ± SEM for % killing values across independent replicates of unique VCM samples. The graphs represent cumulative data from three to four experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.
    Recombinant Human Active Heparanase, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+heparanase/Recombinant+Human+Active+Heparanase%2FHPSE+Protein%2C+CF/pm41406170-398-0-5
    Average 94 stars, based on 1 article reviews
    recombinant human active heparanase - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    recombinant human heparanase rhhpse  (R&D Systems)
    94
    R&D Systems recombinant human heparanase rhhpse
    PMN antifungal activity in VCM spiked with HS or treated with HPSEs. Vaginal swab samples were collected from three groups: women with RVVC experiencing a symptomatic acute episode of VVC (symptomatic group, n = 31), those in asymptomatic remission (asymptomatic group, n = 14), and healthy women without a history of frequent VVC (control group, n = 16). The data sets included an additional five follow-up swabs collected from women in the symptomatic and asymptomatic groups. Detached swab tips were suspended individually in 1 mL RPMI 1640 medium to release vaginal secretions and cellular content. Supernatants were sterile-filtered as VCM. PMNs (5 × 10 5 ) isolated from peripheral blood of healthy volunteers were incubated with C. albicans cells (1 × 10 5 ) in 100 µL of VCM or RPMI medium for 3 h at 37°C with 5% CO 2 . Controls consisted of C. albicans cultured alone in VCM or RPMI medium and were used to calculate % killing. ( A ) VCM samples with normal killing activity (non-inhibitory VCM, gray bar) were spiked with purified porcine HS (500 µg/mL) and reevaluated for PMN killing activity (blue bar). Spiked non-inhibitory VCM was then pretreated with r Ph <t>HPSE</t> (3 ng/mL) and reevaluated for PMN killing activity (red bar). ( B ) VCM samples with low killing activity (inhibitory VCM, solid blue bar) were pretreated with rhHPSE (4 µg/mL, red-dotted bar) or r Ph HPSE (3 ng/mL, red-striped bar) and reevaluated for PMN killing activity. After coculture, viable C. albicans cells were enumerated by quantitative plate counts. Data were analyzed using the one-way ANOVA and Bonferroni’s post-test. Bar heights and error bars represent group means ± SEM for % killing values across independent replicates of unique VCM samples. The graphs represent cumulative data from three to four experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.
    Recombinant Human Heparanase Rhhpse, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+heparanase/Recombinant+Human+Active+Heparanase%2FHPSE+Protein%2C+CF/10__1016_slash_j__carbpol__2025__124760-56-0-7
    Average 94 stars, based on 1 article reviews
    recombinant human heparanase rhhpse - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    recombinant human heparanase  (R&D Systems)
    94
    R&D Systems recombinant human heparanase
    In vitro glycocalyx degradation mediated by <t>heparanase</t> and MMP-9 followed by QCM-D (A) b-HS and (B) rhSDC-1 protein were absorbed on synthetic membrane composed by POPC-DOPE (95:5) lipids and streptavidin, plus Tris-NTA linker for rhSDC-1. After incubation with albumin at 40, 20, or 10 mg/mL, real-time degradation of b-HS by HPSE at 250 ng/mL (C) and rhSDC1 by MMP-9 at 500 ng/mL (D). Arrow indicates when the enzyme is injected. Shift in frequency (Δf) and dissipation (ΔD) due to enzyme activity was measured after enzyme activity in enzyme buffer. Percentage of Δf and ΔD signal reduction for b-HS (E) and rhSDC1 (F) after enzymatic treatment ( n = 4) were calculated from the b-HS or rhSDC-1 signal in enzyme buffer (corresponding to 100%). Data are represented as mean ± SD. Significant differences are indicated by asterisks (∗∗∗ p < 0.001; ∗∗ p < 0.01; and ∗ p < 0.05). QCM-D, quartz crystal microbalance with dissipation; b-HS, biotinylated heparan sulfate; rhSDC-1, <t>recombinant</t> human syndecan-1; MMP-9, matrix metalloproteinase 9; HPSE, human heparanase.
    Recombinant Human Heparanase, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+heparanase/Recombinant+Human+Active+Heparanase%2FHPSE+Protein%2C+CF/pmc12496195-242-0-5
    Average 94 stars, based on 1 article reviews
    recombinant human heparanase - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier
    cf catalog 7570 gh 005 r d systems  (R&D Systems)
    94
    R&D Systems cf catalog 7570 gh 005 r d systems
    In vitro glycocalyx degradation mediated by <t>heparanase</t> and MMP-9 followed by QCM-D (A) b-HS and (B) rhSDC-1 protein were absorbed on synthetic membrane composed by POPC-DOPE (95:5) lipids and streptavidin, plus Tris-NTA linker for rhSDC-1. After incubation with albumin at 40, 20, or 10 mg/mL, real-time degradation of b-HS by HPSE at 250 ng/mL (C) and rhSDC1 by MMP-9 at 500 ng/mL (D). Arrow indicates when the enzyme is injected. Shift in frequency (Δf) and dissipation (ΔD) due to enzyme activity was measured after enzyme activity in enzyme buffer. Percentage of Δf and ΔD signal reduction for b-HS (E) and rhSDC1 (F) after enzymatic treatment ( n = 4) were calculated from the b-HS or rhSDC-1 signal in enzyme buffer (corresponding to 100%). Data are represented as mean ± SD. Significant differences are indicated by asterisks (∗∗∗ p < 0.001; ∗∗ p < 0.01; and ∗ p < 0.05). QCM-D, quartz crystal microbalance with dissipation; b-HS, biotinylated heparan sulfate; rhSDC-1, <t>recombinant</t> human syndecan-1; MMP-9, matrix metalloproteinase 9; HPSE, human heparanase.
    Cf Catalog 7570 Gh 005 R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+heparanase/Recombinant+Human+Active+Heparanase%2FHPSE+Protein%2C+CF/pmc12276975-978-5-9
    Average 94 stars, based on 1 article reviews
    cf catalog 7570 gh 005 r d systems - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    PMN antifungal activity in VCM spiked with HS or treated with HPSEs. Vaginal swab samples were collected from three groups: women with RVVC experiencing a symptomatic acute episode of VVC (symptomatic group, n = 31), those in asymptomatic remission (asymptomatic group, n = 14), and healthy women without a history of frequent VVC (control group, n = 16). The data sets included an additional five follow-up swabs collected from women in the symptomatic and asymptomatic groups. Detached swab tips were suspended individually in 1 mL RPMI 1640 medium to release vaginal secretions and cellular content. Supernatants were sterile-filtered as VCM. PMNs (5 × 10 5 ) isolated from peripheral blood of healthy volunteers were incubated with C. albicans cells (1 × 10 5 ) in 100 µL of VCM or RPMI medium for 3 h at 37°C with 5% CO 2 . Controls consisted of C. albicans cultured alone in VCM or RPMI medium and were used to calculate % killing. ( A ) VCM samples with normal killing activity (non-inhibitory VCM, gray bar) were spiked with purified porcine HS (500 µg/mL) and reevaluated for PMN killing activity (blue bar). Spiked non-inhibitory VCM was then pretreated with r Ph HPSE (3 ng/mL) and reevaluated for PMN killing activity (red bar). ( B ) VCM samples with low killing activity (inhibitory VCM, solid blue bar) were pretreated with rhHPSE (4 µg/mL, red-dotted bar) or r Ph HPSE (3 ng/mL, red-striped bar) and reevaluated for PMN killing activity. After coculture, viable C. albicans cells were enumerated by quantitative plate counts. Data were analyzed using the one-way ANOVA and Bonferroni’s post-test. Bar heights and error bars represent group means ± SEM for % killing values across independent replicates of unique VCM samples. The graphs represent cumulative data from three to four experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.

    Journal: Infection and Immunity

    Article Title: Elevated vaginal heparan sulfate correlates with impaired neutrophil killing of Candida albicans in women with vulvovaginal candidiasis

    doi: 10.1128/iai.00709-25

    Figure Lengend Snippet: PMN antifungal activity in VCM spiked with HS or treated with HPSEs. Vaginal swab samples were collected from three groups: women with RVVC experiencing a symptomatic acute episode of VVC (symptomatic group, n = 31), those in asymptomatic remission (asymptomatic group, n = 14), and healthy women without a history of frequent VVC (control group, n = 16). The data sets included an additional five follow-up swabs collected from women in the symptomatic and asymptomatic groups. Detached swab tips were suspended individually in 1 mL RPMI 1640 medium to release vaginal secretions and cellular content. Supernatants were sterile-filtered as VCM. PMNs (5 × 10 5 ) isolated from peripheral blood of healthy volunteers were incubated with C. albicans cells (1 × 10 5 ) in 100 µL of VCM or RPMI medium for 3 h at 37°C with 5% CO 2 . Controls consisted of C. albicans cultured alone in VCM or RPMI medium and were used to calculate % killing. ( A ) VCM samples with normal killing activity (non-inhibitory VCM, gray bar) were spiked with purified porcine HS (500 µg/mL) and reevaluated for PMN killing activity (blue bar). Spiked non-inhibitory VCM was then pretreated with r Ph HPSE (3 ng/mL) and reevaluated for PMN killing activity (red bar). ( B ) VCM samples with low killing activity (inhibitory VCM, solid blue bar) were pretreated with rhHPSE (4 µg/mL, red-dotted bar) or r Ph HPSE (3 ng/mL, red-striped bar) and reevaluated for PMN killing activity. After coculture, viable C. albicans cells were enumerated by quantitative plate counts. Data were analyzed using the one-way ANOVA and Bonferroni’s post-test. Bar heights and error bars represent group means ± SEM for % killing values across independent replicates of unique VCM samples. The graphs represent cumulative data from three to four experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.

    Article Snippet: To degrade HS, symptomatic (inhibitory) VCM was pretreated with either recombinant human HPSE (rhHPSE, 4 μg/mL, R&D Systems) or recombinant Pedobacter heparinus heparinase III (r Ph HPSE, 3 ng/mL, R&D Systems) for 1 h at 37°C.

    Techniques: Activity Assay, Control, Sterility, Isolation, Incubation, Cell Culture, Purification

    In vitro glycocalyx degradation mediated by heparanase and MMP-9 followed by QCM-D (A) b-HS and (B) rhSDC-1 protein were absorbed on synthetic membrane composed by POPC-DOPE (95:5) lipids and streptavidin, plus Tris-NTA linker for rhSDC-1. After incubation with albumin at 40, 20, or 10 mg/mL, real-time degradation of b-HS by HPSE at 250 ng/mL (C) and rhSDC1 by MMP-9 at 500 ng/mL (D). Arrow indicates when the enzyme is injected. Shift in frequency (Δf) and dissipation (ΔD) due to enzyme activity was measured after enzyme activity in enzyme buffer. Percentage of Δf and ΔD signal reduction for b-HS (E) and rhSDC1 (F) after enzymatic treatment ( n = 4) were calculated from the b-HS or rhSDC-1 signal in enzyme buffer (corresponding to 100%). Data are represented as mean ± SD. Significant differences are indicated by asterisks (∗∗∗ p < 0.001; ∗∗ p < 0.01; and ∗ p < 0.05). QCM-D, quartz crystal microbalance with dissipation; b-HS, biotinylated heparan sulfate; rhSDC-1, recombinant human syndecan-1; MMP-9, matrix metalloproteinase 9; HPSE, human heparanase.

    Journal: iScience

    Article Title: Matrix metalloproteinase-9 mediates endothelial glycocalyx degradation and correlates with severity of hemorrhagic fever with renal syndrome

    doi: 10.1016/j.isci.2025.113262

    Figure Lengend Snippet: In vitro glycocalyx degradation mediated by heparanase and MMP-9 followed by QCM-D (A) b-HS and (B) rhSDC-1 protein were absorbed on synthetic membrane composed by POPC-DOPE (95:5) lipids and streptavidin, plus Tris-NTA linker for rhSDC-1. After incubation with albumin at 40, 20, or 10 mg/mL, real-time degradation of b-HS by HPSE at 250 ng/mL (C) and rhSDC1 by MMP-9 at 500 ng/mL (D). Arrow indicates when the enzyme is injected. Shift in frequency (Δf) and dissipation (ΔD) due to enzyme activity was measured after enzyme activity in enzyme buffer. Percentage of Δf and ΔD signal reduction for b-HS (E) and rhSDC1 (F) after enzymatic treatment ( n = 4) were calculated from the b-HS or rhSDC-1 signal in enzyme buffer (corresponding to 100%). Data are represented as mean ± SD. Significant differences are indicated by asterisks (∗∗∗ p < 0.001; ∗∗ p < 0.01; and ∗ p < 0.05). QCM-D, quartz crystal microbalance with dissipation; b-HS, biotinylated heparan sulfate; rhSDC-1, recombinant human syndecan-1; MMP-9, matrix metalloproteinase 9; HPSE, human heparanase.

    Article Snippet: Recombinant human heparanase (rhHPSE; #7570-GH-005, R&D Systems, Sweden) was diluted in rhHPSE assay buffer comprising 20 mM Tris-HCl and 4 mM CaCl 2 (pH 7.5).

    Techniques: In Vitro, QCM-D, Membrane, Incubation, Injection, Activity Assay, Recombinant

    In vitro endothelial glycocalyx degradation and endothelial barrier disruption followed by impedance measurement (A) SDC-1 staining on ciGEnC cells after incubation with MMP-9 enzyme and increased concentration of albumin (scale bars 20 μm). (B) SDC-1 fluorescence quantification after treatment compared to control (no treatment) (averaged values of 3 sections per condition, n = 3 assays). (C) HS staining on ciGEnC cells after incubation with HSPE enzyme and increased concentration of albumin (scale bars 20 μm). (D) HS fluorescence quantification after treatment compared to control (no treatment) (averaged values of 3 sections per condition, n = 3 assays). (E) Endothelial barrier resistance followed by impedance measurement (ECIS, APBiophysic) on ciGEnC after treatment with MMP-9 and albumin (averaged of 2 values per conditions, n = 3 assays). (F) Endothelial barrier resistance followed by impedance measurement (ECIS, APBiophysic) on ciGEnC after treatment with HSPE and albumin (averaged of 2 values per conditions, n = 3 assays). Data are represented as mean ± SD. Significant differences are indicated by asterisks (∗∗∗ p < 0.001; ∗∗ p < 0.01; and ∗ p < 0.05). HS, heparan sulfate; SDC-1, syndecan-1; MMP-9, matrix metalloproteinase 9; HPSE, human heparanase.

    Journal: iScience

    Article Title: Matrix metalloproteinase-9 mediates endothelial glycocalyx degradation and correlates with severity of hemorrhagic fever with renal syndrome

    doi: 10.1016/j.isci.2025.113262

    Figure Lengend Snippet: In vitro endothelial glycocalyx degradation and endothelial barrier disruption followed by impedance measurement (A) SDC-1 staining on ciGEnC cells after incubation with MMP-9 enzyme and increased concentration of albumin (scale bars 20 μm). (B) SDC-1 fluorescence quantification after treatment compared to control (no treatment) (averaged values of 3 sections per condition, n = 3 assays). (C) HS staining on ciGEnC cells after incubation with HSPE enzyme and increased concentration of albumin (scale bars 20 μm). (D) HS fluorescence quantification after treatment compared to control (no treatment) (averaged values of 3 sections per condition, n = 3 assays). (E) Endothelial barrier resistance followed by impedance measurement (ECIS, APBiophysic) on ciGEnC after treatment with MMP-9 and albumin (averaged of 2 values per conditions, n = 3 assays). (F) Endothelial barrier resistance followed by impedance measurement (ECIS, APBiophysic) on ciGEnC after treatment with HSPE and albumin (averaged of 2 values per conditions, n = 3 assays). Data are represented as mean ± SD. Significant differences are indicated by asterisks (∗∗∗ p < 0.001; ∗∗ p < 0.01; and ∗ p < 0.05). HS, heparan sulfate; SDC-1, syndecan-1; MMP-9, matrix metalloproteinase 9; HPSE, human heparanase.

    Article Snippet: Recombinant human heparanase (rhHPSE; #7570-GH-005, R&D Systems, Sweden) was diluted in rhHPSE assay buffer comprising 20 mM Tris-HCl and 4 mM CaCl 2 (pH 7.5).

    Techniques: In Vitro, Disruption, Staining, Incubation, Concentration Assay, Fluorescence, Control